Absci Corp ABSI
We take great care to ensure that the data presented and summarized in this overview for Absci Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABSI
View all-
Redmile Group, LLC San Francisco, CA8.25MShares$22.9 Million2.06% of portfolio
-
Fred Alger Management, LLC New York, NY7.57MShares$21 Million0.15% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.34MShares$17.6 Million0.23% of portfolio
-
Black Rock Inc. New York, NY5.34MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.94MShares$13.7 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.62MShares$7.26 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.09MShares$5.79 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$5.36 Million0.0% of portfolio
-
State Street Corp Boston, MA1.93MShares$5.34 Million0.0% of portfolio
-
Marshall Wace, LLP London, X01.3MShares$3.61 Million0.01% of portfolio
Latest Institutional Activity in ABSI
Top Purchases
Top Sells
About ABSI
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Insider Transactions at ABSI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 12
2024
|
Andreas Busch Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,092
-1.2%
|
$12,368
$4.07 P/Share
|
Oct 12
2024
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-0.07%
|
$968
$4.07 P/Share
|
Oct 12
2024
|
Todd Bedrick SVP, CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,606
-10.09%
|
$62,424
$4.07 P/Share
|
Oct 12
2024
|
Sean Mc Clain Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,543
-0.18%
|
$58,172
$4.07 P/Share
|
Aug 31
2024
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,775
-5.4%
|
$83,100
$4.4 P/Share
|
Jun 13
2024
|
Zachariah Jonasson CFO / CBO |
SELL
Open market or private sale
|
Direct |
19,859
-4.91%
|
$79,436
$4.98 P/Share
|
Jun 13
2024
|
Zachariah Jonasson CFO / CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,700
+6.62%
|
$86,100
$3.39 P/Share
|
Jun 12
2024
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,820
+0.11%
|
-
|
Jun 12
2024
|
Amrit Nagpal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,820
+50.0%
|
-
|
Jun 12
2024
|
Daniel A Rabinovitsj Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,820
+50.0%
|
-
|
Jun 12
2024
|
Menelas N Pangalos Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,675
+50.0%
|
-
|
Jun 12
2024
|
Frans Van Houten Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,820
+50.0%
|
-
|
Jun 12
2024
|
Karen K Mcginnis Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,820
+27.02%
|
-
|
Jun 12
2024
|
Joseph Sirosh Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,820
+50.0%
|
-
|
May 22
2024
|
Phoenix Venture Partners Ii LP |
SELL
Open market or private sale
|
Direct |
3,100,000
-21.56%
|
$12,400,000
$4.4 P/Share
|
Mar 19
2024
|
Sean Mc Clain Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+15.42%
|
-
|
Mar 01
2024
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
222,222
+2.62%
|
$888,888
$4.5 P/Share
|
Feb 01
2024
|
Todd Bedrick SVP, CAO |
BUY
Grant, award, or other acquisition
|
Direct |
20,570
+11.74%
|
-
|
Feb 01
2024
|
Zachariah Jonasson CFO / CBO |
BUY
Grant, award, or other acquisition
|
Direct |
114,010
+23.27%
|
-
|
Feb 01
2024
|
Andreas Busch Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,125
+24.36%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.96M shares |
---|---|
Open market or private purchase | 222K shares |
Exercise of conversion of derivative security | 28.7K shares |
Payment of exercise price or tax liability | 54.3K shares |
---|---|
Open market or private sale | 3.12M shares |